Saturday 17 October 2026
Export NIKI’s income statement to Excel — free account
Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
2.03
0.19
−8.56%
Follow NIKI
| Dec '25 | Sep '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.90) | (3.77) | (11.01) | (16.25) | |
Capital Expenditures |
0.13 | — | — | 0.14 | |
| Other line items | |||||
Cash ROIC |
(14.05%) | (20.05%) | (55.46%) | (102.24%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | — | — | 0.48 | |
Capex/Depreciation |
0.08 | — | — | 0.06 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | — | 0.00 | |
Capex to Sales |
0.00 | — | — | 0.00 |
Columns are period end dates · fundamentals updated 5 Oct 2026